Coronavirus, Pfizer and BioNTech vaccine is effective in 90% of cases
Well-being — di Andrea Barolini
The Pfizer vaccine has proven effective in 90 per cent of cases and could represent a concrete hope in the fight against coronavirus.
Coronavirus, Pfizer and BioNTech vaccine is effective in 90% of cases
The Pfizer vaccine has proven effective in 90 per cent of cases and could represent a concrete hope in the fight against coronavirus.
A concrete hope is emerging in the fight against Covid-19. The pharmaceutical companies Pfizer and BioNTech have announced that they have a vaccine "effective in 90 per cent of cases". This follows the first interim analysis of their trial, which has reached "phase 3" (the last before a request for approval).
The Pfizer vaccine is at an excellent stage
According to the two companies, immunisation of patients was achieved seven days after the second of two vaccine doses, administered 28 days apart. "Eight months after the first peak of the worst pandemic in more than a century, we believe this milestone represents a significant step forward for the world in the battle against coronavirus," said Pfizer's chief executive officer, Albert Bourla.
UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.
He confirmed that the test results indicate "the ability of our vaccine to prevent the onset of the disease". Pfizer and BioNTech stated that they expect to distribute the first 50 million doses by the end of 2020, and then 1.3 billion doses during 2021.